A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)
Case Comprehensive Cancer Center
Case Comprehensive Cancer Center
National Cancer Institute (NCI)
Wugen, Inc.
Ohio State University Comprehensive Cancer Center
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
The First Affiliated Hospital of Soochow University
Thomas Jefferson University
National Cancer Institute (NCI)
Celgene
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Boehringer Ingelheim
HUYABIO International, LLC.
Kyowa Kirin Co., Ltd.
Stanford University
University of Nebraska
University of Nebraska
University of Nebraska
Emory University
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Goethe University
Atara Biotherapeutics
National Institutes of Health Clinical Center (CC)
Mayo Clinic
Memorial Sloan Kettering Cancer Center
Northwestern University
Roswell Park Cancer Institute
Universität des Saarlandes
Fred Hutchinson Cancer Center
miRagen Therapeutics, Inc.
Mayo Clinic
Jonsson Comprehensive Cancer Center
Jonsson Comprehensive Cancer Center
Case Comprehensive Cancer Center
National Cancer Institute (NCI)
Canadian Cancer Trials Group
Canadian Cancer Trials Group
Mayo Clinic
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
University of Wisconsin, Madison
Mayo Clinic
Roswell Park Cancer Institute
Roswell Park Cancer Institute
Eli Lilly and Company
University of Chicago